KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Cash & Equivalents (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of Cash & Equivalents data on record, last reported at $1.3 billion in Q3 2025.

  • For Q3 2025, Cash & Equivalents fell 40.22% year-over-year to $1.3 billion; the TTM value through Sep 2025 reached $1.3 billion, down 40.22%, while the annual FY2024 figure was $2.4 billion, 60.18% up from the prior year.
  • Cash & Equivalents reached $1.3 billion in Q3 2025 per JAZZ's latest filing, up from $1.2 billion in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $2.4 billion in Q4 2024 and bottomed at $490.8 million in Q1 2022.
  • Average Cash & Equivalents over 5 years is $1.3 billion, with a median of $1.3 billion recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 198.96% in 2021, then tumbled 76.6% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $591.4 million in 2021, then skyrocketed by 49.04% to $881.5 million in 2022, then surged by 70.88% to $1.5 billion in 2023, then skyrocketed by 60.18% to $2.4 billion in 2024, then plummeted by 45.04% to $1.3 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $1.3 billion in Q3 2025, $1.2 billion in Q2 2025, and $1.9 billion in Q1 2025.